Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

About this update from Genmab A/s

[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Media Release COPENHAGEN, Denmark; October 18, 2025","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expression","length":223,"tagName":"p"}]},{"val":[{"type":"text","content":"A Phase 3 trial in endometrial cancer is underway","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer","length":100,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":372,"olType":false},{"type":"text","content":"Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg/m² cohort maintained their responses and remain on treatment. The responses were observed regardless of FRα expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.","length":976,"tagName":"p"},{"type":"text","content":"Continued evaluation of single-agent Rina-S 100 mg/m2 in patient...

More updates from Genmab A/s